New Dual-Targeting CAR t therapy shows promise for Tough-to-Treat lymphoma
Disease control
Ongoing
This study tests a new treatment for people with B-cell Non-Hodgkin's lymphoma that has come back or stopped responding to standard therapy. The treatment uses a patient's own immune cells that are modified to target two proteins (CD19 and CD20) on cancer cells, plus a drug calle…
Phase: PHASE1, PHASE2 • Sponsor: Han weidong • Aim: Disease control
Last updated May 02, 2026 17:15 UTC